These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
349 related articles for article (PubMed ID: 30594250)
1. Development of multi-criteria decision analysis (MCDA) framework for off-patent pharmaceuticals - an application on improving tender decision making in Indonesia. Inotai A; Brixner D; Maniadakis N; Dwiprahasto I; Kristin E; Prabowo A; Yasmina A; Priohutomo S; Németh B; Wijaya K; Kalo Z BMC Health Serv Res; 2018 Dec; 18(1):1003. PubMed ID: 30594250 [TBL] [Abstract][Full Text] [Related]
2. Applying Multi-Criteria Decision Analysis (MCDA) Simple Scoring as an Evidence-based HTA Methodology for Evaluating Off-Patent Pharmaceuticals (OPPs) in Emerging Markets. Brixner D; Maniadakis N; Kaló Z; Hu S; Shen J; Wijaya K Value Health Reg Issues; 2017 Sep; 13():1-6. PubMed ID: 29073981 [TBL] [Abstract][Full Text] [Related]
3. An Evidence Framework for Off-Patent Pharmaceutical Review for Health Technology Assessment in Emerging Markets. Brixner D; Kaló Z; Maniadakis N; Kim K; Wijaya K Value Health Reg Issues; 2018 Sep; 16():9-13. PubMed ID: 29605800 [TBL] [Abstract][Full Text] [Related]
4. A multi-criteria decision analysis (MCDA) tool for purchasing off-patent oncology medicines in Egypt. Elezbawy B; Fasseeh AN; Sedrak A; Eldessouki R; Gamal M; Eldebeiky M; Amer H; Akeel S; Morsy A; Amin A; Shafik A; Abaza S; Kaló Z J Pharm Policy Pract; 2022 Mar; 15(1):10. PubMed ID: 35232487 [TBL] [Abstract][Full Text] [Related]
5. Recommendation for a Pilot MCDA Tool to Support the Value-Based Purchasing of Generic Medicines in the UAE. Farghaly MN; Al Dallal SAM; Fasseeh AN; Monsef NA; Suliman EAMA; Tahoun MA; Abaza S; Kaló Z Front Pharmacol; 2021; 12():680737. PubMed ID: 34168564 [No Abstract] [Full Text] [Related]
7. Stakeholder driven development of a multi-criteria decision analysis tool for purchasing off-patent pharmaceuticals in Kuwait. Abdullah AH; Holtorf AP; Al-Hussaini M; Lemay J; Alowayesh M; Kaló Z J Pharm Policy Pract; 2019; 12():9. PubMed ID: 31011430 [TBL] [Abstract][Full Text] [Related]
8. A Case Study of Pharmaceutical Pricing in China: Setting the Price for Off-Patent Originators. Hu S; Zhang Y; He J; Du L; Xu M; Xie C; Peng Y; Wang L Appl Health Econ Health Policy; 2015 Aug; 13 Suppl 1(Suppl 1):S13-20. PubMed ID: 26091710 [TBL] [Abstract][Full Text] [Related]
9. Shaping Pharmaceutical Tenders for Effectiveness and Sustainability in Countries with Expanding Healthcare Coverage. Maniadakis N; Holtorf AP; Otávio Corrêa J; Gialama F; Wijaya K Appl Health Econ Health Policy; 2018 Oct; 16(5):591-607. PubMed ID: 29987759 [TBL] [Abstract][Full Text] [Related]
10. Multicriteria decision analysis (MCDA) for health technology assessment: the Queensland Health experience. Howard S; Scott IA; Ju H; McQueen L; Scuffham PA Aust Health Rev; 2019 Oct; 43(5):591-599. PubMed ID: 30205873 [TBL] [Abstract][Full Text] [Related]
11. A multicriteria decision analysis (MCDA) tool to purchase implantable medical devices in Egypt. Elezbawy B; Fasseeh AN; Németh B; Gamal M; Eldebeiky M; Refaat R; Taha A; Rabiea S; Abdallah M; Ramadan S; Noaman H; Eldin AB; Mostafa H; Nouh S; Zaki A; Abdelrahman M; Abaza S; Kalò Z BMC Med Inform Decis Mak; 2022 Nov; 22(1):289. PubMed ID: 36352382 [TBL] [Abstract][Full Text] [Related]
12. How drug life-cycle management patent strategies may impact formulary management. Berger J; Dunn JD; Johnson MM; Karst KR; Shear WC Am J Manag Care; 2016 Oct; 22(16 Suppl):S487-S495. PubMed ID: 28719222 [TBL] [Abstract][Full Text] [Related]
13. Case studies for implementing MCDA for tender and purchasing decisions in hospitals in Indonesia and Thailand. Holtorf AP; Kristin E; Assamawakin A; Upakdee N; Indrianti R; Apinchonbancha N J Pharm Policy Pract; 2021 Jun; 14(1):52. PubMed ID: 34127071 [TBL] [Abstract][Full Text] [Related]
14. Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study. Gupta R; Bollyky TJ; Cohen M; Ross JS; Kesselheim AS BMJ; 2018 Mar; 360():k831. PubMed ID: 29555641 [TBL] [Abstract][Full Text] [Related]
15. On macroeconomic characteristics of pharmaceutical generics and the potential for manufacturing and consumption under fuzzy conditions. Gascón F; de la Fuente D; Puente J; Lozano J Artif Intell Med; 2007 Nov; 41(3):223-35. PubMed ID: 17719212 [TBL] [Abstract][Full Text] [Related]
16. A comparative analysis of generics markets in five European countries. Garattini L; Tediosi F Health Policy; 2000 Apr; 51(3):149-62. PubMed ID: 10720685 [TBL] [Abstract][Full Text] [Related]